Rituximab monotherapy for primary cutaneous B-cell lymphoma: Response and follow-up in 16 patients

Annals of Oncology

Volumn 20, Issue 2, 2009, Pages 326-330

  Valencak, J ^a   Weihsengruber, F ^b   Rappersberger, K ^b   Trautinger, F ^c   Chott, A ^d   Streubel, B ^d   Muellauer, L ^d   Der Petrossian, M ^a   Jonak, C ^a   Binder, M ^a   Raderer, Markus ^d  

^a Universitatsklinik fur Dermatologie   (Austria)

^b KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^c Karl Landsteiner Institute for Implementation of Innovative Techniques in Cardiac Surgery   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cutaneous B cell lymphoma; Rituximab; Systemic treatment

Indexed keywords

DIPHENHYDRAMINE; FLUDARABINE; PARACETAMOL; RITUXIMAB;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CHROMOSOME G BAND; CHROMOSOME REARRANGEMENT; CLINICAL ARTICLE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLUSHING; FOLLOW UP; HEAT SENSATION; HUMAN; KARYOTYPE; MALE; MONOTHERAPY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; SIDE EFFECT; SKIN LYMPHOMA;

EID: 60549110678     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn636     Document Type: Article

References (20)

1. Isaacson PG, Norton AJ. Cutaneous lymphoma. In Isaacson PG, Norton AJ (eds): Extranodal Lymphomas. London: Churchill Livingstone 1994; 131-191.
2. Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
3. Burke JS, Hoppe RT, Cibull ML, Dorfman RF. Cutaneous malignant lymphoma: a pathologic study of 50 cases with clinical analysis of 37. Cancer 1981; 47: 300-310.
4. Wood GS, Burke JS, Horning S et al. The immunologic and clinicopathologic heterogeneity of cutaneous lymphoma other than mycosis fungoides. Blood 1983; 62: 464-472.
5. Zinzani PL, Quaglino P, Pimpinelli N et al. Prognostic factors in primary cutaneous B-cell lymphoma: The Italian Study Group for cutaneous lymphomas. J Clin Oncol 2006; 24: 1376-1382.
6. Bogle MA, Riddle CC, Triana EM et al. Primary cutaneous B-cell lymphoma. J Am Acad Dermatol 2005; 53: 479-484.
7. Santucci M, Pimpinelli N. Primary cutaneous B-cell lymphomas. Current concepts. I. Haematologica 2004; 89: 1360-1371.
8. Smith BD, Glusac EJ, McNiff JM et al. Primary cutaneous B-cell lymphoma treated with radiotherapy: A comparison of the European Organization for Research and Treatment of Cancer and the WHO classification systems. J Clin Oncol 2004; 22: 634-639.
9. Pandolfino TL, Siegel RS, Kuzel TM et al. Primary cutaneous B-cell lymphoma: Review and current concepts. J Clin Oncol 2000; 18: 2152-2168.
10. Molina A. A decade of rituximab: Improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med 2008; 59: 237-250.
11. Gitelson E, Al-Saleem T, Millenson M et al. Cutaneous B-cell lymphoma responds to rituximab: A report of five cases and review of the literature. Leuk Lymphoma 2006; 47: 1902-1907.
12. Nagasaka A, Matsue H, Kawamura T et al. Complete remission of a primary cutaneous follicle-center cell lymphoma (EORTC criteria)/diffuse large B-cell lymphoma (WHO criteria) by single first-line therapy with rituximab. J Dermatol 2006; 33: 377-379.
13. Kerl K, Prins C, Saurat JH, French LE. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: Report and follow-up of eight cases. Br J Dermatol 2006; 155: 1197-1200.
14. Kyrtsonis MC, Siakantaris MP, Kalpadakis C et al. Favourable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. Eur J Haematol 2006; 77: 300-303.
15. Gellrich S, Muche JM, Wilks A et al. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas-an applicational observation. Br J Dermatol 2005; 153: 167-173.
16. Heinzerling LM, Urbanek M, Funk JO et al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer 2000; 89: 1835-1844.
17. Wobser M, Voigt H, Eggert AO et al. Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma. Br J Cancer 2007; 96: 1540-1543.
18. Streubel B, Streubel B, Scheucher B et al. Molecular cytogenetic evidence of t(14;18)(IGH;BCL2) in a substantial proportion of primary cutaneous follicle center lymphomas. Am J Surg Pathol 2006; 30: 529-536.
19. Grange F, Beylot-Barry M, Courville P et al. Primary cutaneous diffuse large B-cell lymphoma, leg type. Clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol 2007; 143: 1144-1150.
20. Smith B, Glusac E, McNiff J et al. Primary cutaneous B-cell Lymphoma treated with radiotherapy: A comparison of the European Organization for Research and Treatment Cancer and the WHO classification systems. J Clin Oncol 2004; 22: 634-639.